Telehealth payments

Payment Processing for GLP-1 and Weight-Loss Telehealth: What Underwriters Ask in 2026

A weight-loss telehealth application gets read question by question. These are the questions, why each one is asked in 2026, and what a complete answer looks like.

By VyaPayPublished 8 min read

Expect an underwriter to ask a GLP-1 telehealth company six things: what it dispenses (an FDA-approved brand or a compounded drug), which pharmacy makes and ships it, whether it holds LegitScript certification, what its marketing claims, how its memberships bill and cancel, and how much patients prepay. Each answer moves the risk on the account, and FDA's shortage decisions of late 2024 and early 2025 made the first question harder to answer than it used to be.

A GLP-1 telehealth program is a business in which clinicians evaluate patients remotely and prescribe GLP-1 medications such as semaglutide or tirzepatide, which a pharmacy then dispenses and ships. It may bill per visit, as a monthly membership or as a prepaid multi-month plan, and its payment risk depends on which of those it uses and who charges for the drug.

What are you dispensing: an FDA-approved drug or a compounded one?

This question comes first because FDA's position on compounded GLP-1s changed in 2025, and the underwriter needs to know which side of that change your product sits on. FDA declared the tirzepatide shortage resolved (a determination it reaffirmed on December 19, 2024) and the semaglutide shortage resolved on February 21, 2025. The enforcement-discretion periods it gave compounders ended in 2025: February 18 (503A) and March 19 (503B) for tirzepatide, April 22 (503A) and May 22 (503B) for semaglutide. Since those dates, in FDA's stated position, compounders can no longer rely on the shortage to make essentially copies of the approved drugs.

FDA has also said, on its page on unapproved GLP-1 drugs (content current as of October 1, 2026), that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients and that it is "not aware of any lawful basis" for their use in compounding.

We don't decide whether a particular compounded product is lawful, and a processor's sales team shouldn't either. What the underwriter needs is precise information: the active ingredient as labelled, the dosage forms, the pharmacy that makes it, and the basis on which that pharmacy says it can compound it. The full sequence of FDA statements, with dates, is in what FDA has said about compounded semaglutide and tirzepatide.

Which pharmacy fills the prescriptions?

The underwriter wants the pharmacy's name, licenses and federal status, because the risk in a compounded product sits with whoever made it. Under §503A of the Food, Drug, and Cosmetic Act, a state-licensed pharmacy compounds on a valid prescription for an identified patient and may not compound essentially copies of commercially available drugs regularly or in inordinate amounts. Under §503B, an outsourcing facility registers with FDA, works under current good manufacturing practice (CGMP), is subject to FDA inspection and reports its products to FDA.

Expect to be asked for the supply contract and a sample label as well. FDA says some compounded products carry false label information, naming pharmacies that don't exist or that didn't make the product, and its warning letters have cited telehealth brands that implied they were the compounder. A label that names the real pharmacy, matching your contract, answers both points.

The underwriter will also ask who charges the patient for the medication. If your company does, you are selling prescription drugs, which, on our reading of Visa's rules, brings its high-integrity risk requirements for non-face-to-face pharmaceutical sales into the file. If the pharmacy charges the patient, your account carries the consult and membership fees.

Do you hold LegitScript certification?

LegitScript says its certification is "a necessary part of the approval process" for card-not-present transactions with Visa and Mastercard, and for advertising on Google and Bing (Healthcare Certification FAQ, read November 2026). Telemedicine providers are among the businesses it lists as generally eligible. As of November 2026 its fees are $975 to apply and $2,150 a year once approved, each per root domain.

If your application is in progress, say so and give the date you applied. LegitScript also asks certified businesses to tell it about changes in ownership, partners, websites, services and jurisdictions, so a new pharmacy partner is a change to report to LegitScript as well as to your acquirer.

What does your marketing say?

Underwriters read your ads because FDA and the FTC have been reading them. FDA lists claims that a compounded drug "is the same as" an FDA-approved drug, and prices that seem too good to be true, among the red flags for consumers. Its warning letters to telehealth sellers of compounded GLP-1s, in rounds dated February 20, 2026 and June 8, 2026 among others, cited claims such as "contains the same active ingredient as FDA-approved medications". FDA has also warned telehealth companies marketing unapproved drugs such as retatrutide.

The FTC's case against NextMed, settled in July 2025 for $150,000, is the other reference point. The FTC alleged that NextMed lacked substantiation for its average weight-loss claims and used fake testimonials and before-and-after photos. Those were allegations resolved by settlement, not findings, but they are the claims an underwriter will look for in your funnel.

Send your live ads, landing pages and any rules you give affiliates or creators. The claims to cut, and why each one draws attention, are covered in GLP-1 advertising rules for telehealth.

Building a GLP-1 program?

Walk through your pharmacy, billing and marketing with the team that makes the underwriting call.

Talk to VyaPay

How do your memberships bill and cancel?

Clearly, if you want the account to last. Visa's §5.4.2.5 requires a merchant that restricts cancellation or refunds to disclose that policy in the checkout sequence before final checkout, with a click-to-accept button, checkbox or other acknowledgement. Visa also has a dispute condition, 13.2, for cancelled recurring transactions, and a membership that is hard to leave invites them.

The NextMed complaint is specific here too. The FTC alleged that the membership, at about $138 or $188 a month, didn't adequately disclose that drugs, labs and consults cost extra, that members were held to one-year terms billed every 28 days, and that cancelling was made hard. On the federal rule itself: as of November 2026 the FTC's 2024 click-to-cancel amendments stand vacated by the Eighth Circuit (July 2025), the FTC restored the pre-2024 rule text in February 2026 and opened a new rulemaking with an advance notice in March 2026, and ROSCA still applies to online negative-option sales.

Send screenshots of the checkout showing the price, what it excludes, the billing interval and the cancellation terms, plus the cancellation flow itself.

How much do patients prepay?

A prepaid three- or six-month plan collects money now for medication shipped later, and that gap is what the underwriter prices. If the pharmacy can't ship, or the patient stops treatment in month two, the refunds and disputes arrive after the money has been paid out. A reserve is one way a processor covers that window. We won't quote reserve terms here, because they depend on the file, but the mechanics are in why processors hold reserves on telehealth accounts.

The useful numbers to bring are the share of your volume that is prepaid, the longest plan you sell, your shipping cadence, and your refund policy for months not yet shipped.

What's your dispute history, and what should you send?

Recent processing statements with dispute counts by reason, if you have processed before. Visa's VAMP threshold for merchants in the US dropped to 1.5% on April 1, 2026, as acquirers and chargeback vendors report it, so the underwriter will compute your ratio either way. Breaking disputes down by Visa condition (13.1 not received, 13.2 cancelled recurring, 13.3 not as described, 10.4 card-absent fraud) shows whether they come from shipping, billing or marketing.

Underwriter's questionWhat a complete answer includes
What do you dispense?Product list by active ingredient as labelled, approved brand or compounded, dosage forms
Which pharmacy?Name, state licenses, 503A or 503B status, supply contract, sample label
LegitScript?Certification status and date, or application date
Marketing?Live ads, landing pages, affiliate and creator rules
Billing and cancellation?Checkout screenshots, terms, cancellation flow, renewal notices
Prepaid exposure?Share of prepaid volume, longest plan, refund policy for unshipped months
Disputes?Statements, counts by Visa condition, refund volume

The full document list for any telehealth business, GLP-1 or not, is in the telehealth merchant account application checklist. VyaPay runs its own processor and underwrites in-house, so these answers go to the team that makes the decision and then keeps the account live; start that conversation here.

Frequently asked questions

Can a GLP-1 telehealth company get a merchant account if it sells compounded medication?

There's no general answer, and no processor should give one before reading the file. Underwriters look at the specific product, the pharmacy and its federal status, your marketing and your billing. Whether a specific product can lawfully be compounded is a question for your regulatory counsel.

Does selling only FDA-approved brands make underwriting simpler?

It removes the compounding questions and leaves the rest. If you charge for the medication, the account still sells prescription drugs, and marketing, membership terms and prepaid exposure are read the same way.

Why does a processor want to see my ads?

FDA's warning letters and the FTC's NextMed complaint were both about marketing claims, so ads making the same claims carry the same exposure. The acquirer also answers to Visa, which under §1.9.1.4 can act on brand-damaging transaction activity.

Can we compare our price with the brand-name drug in ads?

Expect an underwriter to ask about it if you do. FDA lists prices that seem too good to be true among its consumer red flags, next to claims that a compounded drug is the same as an approved one, and in our view a side-by-side with a brand-name price can read as both.

Sources

Talk to the team that underwrites you

Tell us what you prescribe or sell, how you bill and who your pharmacy partners are. You'll be talking to the people who run VyaPay's processor and make its risk decisions.

or call 833-4-VYAPAY

Let’s meet up!

Tell us about your business and someone from our team will reach out.